Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

27 Apr 2022

Abstract excerpt

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the tumor-intrinsic alterations underlying these phenomena remain undefined. CD19 mutations associate with resistance but are uncommon, and most patients with relapsed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Integrated Circuits and Semiconductor Failure Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35476848
DOI: 10.1182/blood.2021015008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaPMID 35476848Read ↗

Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity Read ↗

<i>RHOA</i> Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell LymphomaSemantic proximity Read ↗

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphomaSemantic proximity Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.Semantic proximity Read ↗

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesSemantic proximity Read ↗

The pan-cancer analysis uncovers the prognostic and immunotherapeutic significance of CD19 as an immune marker in tumorSemantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance.Semantic proximity Read ↗

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling <i>CD19</i> splicing and CART-19 therapy resistanceSemantic proximity Read ↗

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopeniasSemantic proximity Read ↗

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19Semantic proximity Read ↗

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.